We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Carclo Plc | CAR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 5.58 | 75.08% | 13.00 | 16:35:26 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.65 | 9.65 | 13.50 | 13.00 | 7.425 |
| Industry Sector |
|---|
| CHEMICALS |
| Top Posts |
|---|
Posted at 21/8/2023 19:57 by queeny2 Following CAR won't make you live longer, but it'll certainly feel like that. |
Posted at 15/12/2022 08:38 by dougmachin I'm not too fussed about CAR, a smaller position that I'm just letting run.But I think the directors buying shares when they know there's an issue (aka they bought shares after the contraction cancellation announcement), surely this could be seen as a positive. They're aligning themselves with their shareholders. And they're using their buying price to say this should be the limit of the downside. |
Posted at 11/10/2022 08:40 by garth Any thinking in general and any concerned thoughts specifically about current turmoil around sovereign debt and repercussions for the pension committments at CAR down the line.I'll be honest, I think I know enough to be concerned but not enough to know how concerning current moves by the BoE ought to make me about short, medium and longer term here.Thoughts appreciated.G. |
Posted at 16/9/2022 16:38 by ali47fish first equity increases from 3 to 5pc approximately |
Posted at 08/7/2022 15:40 by catch007 Given the likely continued increase in base rate the discount rate used for the pension deficit will improve the net annual position. I think CAR is way oversold at these share price levels. |
Posted at 04/7/2022 17:14 by napoleon 14th wigwammer - I have some CAR; 2% of PF & 15% down, so my only regret is not selling all at 60p - a bit obvious!Your comments are a lot fairer than S C Life, which is always hard on shares they review - I've seen that often with them. Still, harsh realism is needed at times. It was more needed six months ago! There's a presentation of the prelims on Investor Meets Company at 10:00 tomorrow. I hope you see this in time if interested, & that a brighter picture will be shown. "This is a reminder that CARCLO PLC will be holding the meeting Preliminary Results tomorrow at 5th Jul 2022 at 10:00am BST. Please click on the button below accept the meeting invitation." Costs nowt, only need to log on before 10:00 |
Posted at 02/7/2022 13:31 by wigwammer Thanks for posting napoleon, but that is a poor research by small caps life.. 1) they are too pessimistic about dividend reinstatement because they assume the actuarial deficit and related payments are fixed ad infinitum, when in fact they are reviewed every 3 years. The level of actuarial liabilities are highly sensitive to the discount rate - the IAS liabilities sensitivity for example is 16% for every 1% move in the discount rate. Using March 2021 data, the prelim actuarial assessment estimated the liabilities at around £250m, but since then the discount rate has moved from 2%, to around 4%. Taken on it own this would suggest a circa 30% or £75m reduction in the liability, nearly the entire actuarial deficit. A materially lower deficit would likely mean materially lower pension payments. Of course, this will likely not help much with the payments review to be completed in July, but does suggest that dividend payments may be reinstated long before the "decade" that small caps life believe is a clear inevitability.. 2) small caps life are wrong to state that using a PE is inappropriate for an indebted company. The EPS used in the PE calculation is AFTER interest paid, meaning the measure does adjust for interest paid and consequently the scale of debt... 3) small caps life have miscalculated their earnings yield. They state that even assuming 30% EPS growth gets them to a 3.8% earnings yield for next year. In fact, the reported underlying EPS from the year just reported was 3.1p, and adding 30% gets you to 4p. At a share price of 22p, this results in an earnings yield of 18.1%, far higher than the 3.8% small caps life state... in short, be careful taking anything small caps life tell you at face value, sounds like poor quality stuff.. ATB |
Posted at 01/7/2022 17:02 by napoleon 14th A very hard take on CAR by Small Caps Life:Carclo (CAR.L) - Final Results On first glance, a company on a P/E of around 8 and growing EPS at 30% looks good value. However, those who know the history here know that it is a company that got itself in serious trouble and had to sell of one of its largest subsidiaries when it couldn't afford to invest to turn it around. This is a £17m market cap company, but the debt excluding IFRS16 is £21.5m. So a P/E ratio is not a suitable way to value such a business. Then on top of this is a large pension deficit. The IAS19 deficit has been reducing with higher discount rates: However, as we know, the IAS19 deficit is largely irrelevant when it comes to the actual payments made by the company. Here they have agreed to £3.5m per year, with the aim to eliminate the deficit within about 20 years!! It is clear that the company is not going to be in a position to pay any dividends to shareholders for about a decade with these debt & pension deficit levels. The outlook is positive but cautious: "The Board expects market demand for both the CTP and Aerospace divisions to continue to grow in the next financial year but also that the headwinds that prevailed in the second half will continue during the first half." Even if we were super generous and assumed a further 30% growth in EPS in FY23, and that the reduced IAS19 deficit was now realistic, then this is on a forward earnings yield of 3.8%. In the current market, there are much better quality companies, with better long-term prospects, that are much less risky and have much higher earnings yields. Being less generous, given the size of the debt and Pension Deficit, it is still not clear that Carclo's equity has any value at all. investegate.co.ukinv Investegate |Carclo plc Announcements | Carclo plc: Final Results Investegate announcements from Carclo plc, Final Results |
Posted at 28/6/2022 17:07 by wigwammer Dangersimpson, please try to keep it civilised. Using terms like "greater fool" is a bit silly and unhelpful. It feels rather like you are matching your projections to suit a preconceived view that CAR is uninvestible. With liabilities of £203m and assets of £169m, why on earth would it cost a large insurance company an additional £150m to plug the gap? If anything, the trustees would be more comfortable with the security offered by the large liquidity pool of the typical insurance major, than the smaller and less secure cash flows from Carclo. |
Posted at 09/8/2021 15:11 by rivaldo A rare event - CAR have posted some news :o))"Carclo Technical Plastics Announces Med-Tech Innovation Attendance 27 July 2021 London (UK), 27 July 2021: Following the global pandemic and the reduction in exhibition activity, Carclo Technical Plastics (Carclo) announces that it will be exhibiting on stand no E18 at the Med-Tech Innovation Expo at the National Exhibition Centre in Birmingham, UK, now scheduled to be held 28-29 September 2021. Carclo staff will be available to discuss the use of state-of-the-art Pressure Sensing technology for optimisation, monitoring and control of the Injection Moulding process, see attached photo. Carclo has invested significantly in advanced process monitoring equipment and personnel training/development Commenting, Divisional Chief Executive Officer Robert Stutzman stated “Carclo Technical Plastics has ambitious plans to continue developing our medical business, supported by Carclo’s engineering skills, global footprint and financial stability. Carclo considers the Med-Tech Innovation Expo as a key part of our annual marketing activities and we invite all customers and prospective customers to meet with us during this show.” Carclo Technical Plastics is a contract manufacturer which specialises in injection moulding and assembly of thermoplastic components and devices for the medical, diagnostics, electronics, optics and automotive safety markets. With ISO13485-accredited production facilities in Eastern and Western USA, UK, Czech Republic, China and India, Carclo offers its global footprint to customers in these dynamic markets. Carclo’s clients range from globally-located divisions of major healthcare corporations to start-up companies who are developing products for the innovative yet highly-regulated medical industry. Typical products include medical and surgical disposables; drug delivery devices; diagnostic reagent packs; diagnostic components and devices; and ophthalmic equipment, lenses and optical components." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
